Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

Dynamic Top Pick List How to start 2026?

How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...

Local Champions Mid Cap Conference Book 11.12.2025

This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB

Morning Notes : CRBN NA, GIMB BB, HAL NA

: CRBN NA, GIMB BB, HAL NA

Corbion Strategy update shows increased focus, upgrade to BUY

Corbion's BRIGHT 2030 strategy update revealed an increasing focus on clean label Food Ingredients, Nutrition and Biomedical Polymers/Pharma. Biochemicals are being de-prioritized and the strategic ownership review on PLA will most likely result in an exit. Financial targets include a 3-6% annual organic sales growth target and a c 2pp increase in the adjusted EBITDA margin by 2028. A disciplined approach on capex is expected to result in an average 8% FCF yield in the coming years with a streng...

Onward Medical Uneventful 3Q25 results, pivotal Empower BP trial to st...

Onward reported its 3Q25 results, which show no major surprises as the company previously announced the sale of 40 devices in the US in a preliminary update. With a cash position of € 77.7m, Onward is funded into 1Q27 assuming no drawdown of its debt facility. In the pipeline, timelines were reiterated and the company continues to expect to initiate the pivotal Empower BP trial of the ARC-IM system in blood pressure instability by YE25, which means interim results could come in 2H26. We reiterat...

Morning Notes : BESI NA, EVS BB, FAGR BB, IVA FP, MONT BB, SEQUA BB, O...

: BESI NA, EVS BB, FAGR BB, IVA FP, MONT BB, SEQUA BB, ONWD BB

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 11/21/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 21/11/2025

Benelux Morning Notes

Ackermans & van Haaren: 3Q TU mostly in line, better inflows, markets support AuMs. Ahold Delhaize: Peer Walmart 3Q25/26 results. Bekaert: Soft 3Q25 update, FY guidance further toned down. Corbion: Evolution, not revolution. Universal Music Group: Peer Warner Music 11% revenue and 8% OIBDA beat

Morning Notes : ACKB BB, BEKB BB, CRBN NA

: ACKB BB, BEKB BB, CRBN NA

Corbion Feedback CMD

Below we list the key highlights from the CMD. We remind that Corbion announced new financial targets for 2026-2028 including a 3-6% organic sales growth target (KBCS 3.0%) and an 18% adjusted EBITDA margin target (KBCS 17%), vs a 16.3% margin YTD. The announced strategic review on PLA is no surprise and will most likely result in an exit of Corbion, while still remaining the lactic acid supplier to the buyer. Biochemicals will be de-emphasized, which will put the growth focus on food preservati...

Corbion N.V. : A decent CMD update, albeit without the real spice

Barco/More modest improvement/BUY

We maintain our Buy rating, reflecting our continued confidence in Barco's positioning within its niche markets and the ongoing enhancements to its product lineup. However, after the company communicated more modest long-term growth and margin objectives at the CMD, we have reduced our forecasts and, as a result, lowered our target price to €16.0 (previously €17.5).

Benelux Morning Notes

Corbion: Better to travel than to arrive. Gimv: Portfolio return of 9.5% over 1H25, NAV in-line with INGF. IBA: 2025 guidance confirmed, debt high at €60m, €135m of long term financing. Wereldhave: €120m acquisition at 8% NIY, c.€80m capital increase

Morning Notes : ATEB BB, CRBN NA, GIMB BB, IBAB BB

: ATEB BB, CRBN NA, GIMB BB, IBAB BB

Corbion FIRST LOOK: CMD review PLA, focus on food, algae & biomedical/...

Corbion's announced ambitious new financial targets for 2026-2028 including a 3-6% organic sales growth target (KBCS 3.0%) and an 18% adjusted EBITDA margin target (KBCS 17%). Unsurprisingly (given the volatile track record), a strategic review on PLA is being initiated, which we believe will result in an eventual exit. Biochemicals will be de-emphasized, which will put the growth focus on food preservation and formulation, algal oils and Biomedical Polymers/Pharma. We continue to appreciate Cor...

Corbion/Goldilocks scenario; no more bears/HOLD(previously Sell)

In April, we reduced our Corbion forecasts and 12-month target price to account for the double pronged attack on profits from weaker fish oil prices and weaker currencies. We are now in the position of reversing this change due to a Goldilocks scenario in which fish oil prices have risen by 21% in a week, combined with a significant tailwind from a c.25% decline in the sugar price this year. This should drive sustained margin expansion over the next two years and as a result of these changes, ou...